Astellas Vaprisol supplemental approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Astellas' vasopressin antagonist Vaprisol (conivaptan) is approved for a second indication to treat patients with hypervolemic hyponatremia, the Japanese firm announces March 2. Vaprisol was initially approved Dec. 29, 2005 for use in euvolemic hyponatremia (1Pharmaceutical Approvals Monthly January 2006, p. 3). An "approvable" letter for the hypervolemic claim was issued simultaneously...